JHVEPhoto Shares of Amgen (NASDAQ:AMGN) surged after the company reported first quarter results, but the gain was largely driven by management comments related to the phase 2 trial of the long-acting obesity candidate maridebart cafraglutide (which was previously called AMG133), or MariTide as it is conveniently called. No results were reported, but the comments about…
magnetcreative/E+ via Getty Images Eli Lilly (LLY) has been a phenomenal stock to own over the past couple of years. In early 2022, it was trading for about $230 per share, but today it trades for nearly $800. This huge run is largely due to the success of its obesity drug, “Zepbound”. Eli Lilly shares…
malerapaso Introduction Last year, I started covering drug manufacturing giant Amgen Inc. (NASDAQ:AMGN). On June 30, I wrote an article titled “Amgen: A Healthcare Bargain With A 4% Yield.” Since then, shares are up 41%, beating the 9.5% performance of the S&P 500 (SP500) by a wide margin. This rally restored the company’s longer-term performance,…
sefa ozel/iStock via Getty Images Investment Thesis In this analysis of Amgen Inc. (NASDAQ:AMGN), I will dive into a biotech frontrunner renowned for its innovative therapies. As I comprehend and relay my perspective on the company’s journey and scrutinize its financial health, you will be guided through a piece describing and highlighting the recent news…
Grand Warszawski Introduction Amgen (NASDAQ:AMGN) is back. After writing an article titled Amgen: A Healthcare Bargain With A 4% Yield in June, the stock has added 11%, beating the S&P 500 by roughly 9%. While that’s good news, it’s not the reason I’m writing this article. What is even more significant is that this rally…